Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation

Giovanna Lucchini, Myriam Labopin, Eric Beohou, Arnauld Dalissier, Jean Hughes Dalle, Jacqueline Cornish, Marco Zecca, Sujith Samarasinghe, Brenda Gibson, Franco Locatelli, Yves Bertrand, Fawzi Abdel-Rahman, Gerald Socie, Mikael Sundin, Arjan Lankester, Peter Sedlacek, Rose Marie Hamladji, Carsten Heilmann, Boris Afanasyev, Rachel HoughCristina Peters, Peter Bader, Paul Veys

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Hematopoietic stem cell transplantation (HSCT) represents the cornerstone of treatment in pediatric high-risk and relapsed acute myeloid leukemia (AML). The aim of the present study was to compare outcomes of pediatric patients with AML undergoing HSCT using 3 different conditioning regimens: total body irradiation (TBI) and cyclophosphamide (Cy); busulfan (Bu) and Cy; or Bu, Cy, and melphalan (Mel). In this retrospective study, registry data for patients > 2 and <18 years age undergoing matched allogeneic HSCT for AML in first complete remission (CR1) in 204 European Group for Blood and Marrow Transplantation centers between 2000 and 2010 were analyzed. Data were available for 631 patients; 458 patients received stem cells from a matched sibling donor and 173 from a matched unrelated donor. For 440 patients, bone marrow was used as stem cell source, and 191 patients received peripheral blood stem cells. One hundred nine patients received TBICy, 389 received BuCy, and 133 received BuCyMel as their preparatory regimen. Median follow-up was 55 months. Patients receiving BuCyMel showed a lower incidence of relapse at 5 years (14.7% versus 31.5% in BuCy versus 30% in TBICy, P < .01) and higher overall survival (OS) (76.6% versus 64% versus 64.5%, P = .04) and leukemia-free survival (LFS) (74.5% versus 58% versus 61.9%, P < .01), with a comparable nonrelapse mortality (NRM) (10.8% versus 10.5% versus 8.1%, P = .79). Acute graft-versus-host disease (GVHD) grades III and IV but not chronic GVHD, was higher in patients receiving BuCyMel. Older age at HSCT had an adverse impact on NRM and the use of peripheral blood as stem cell source was associated with increased chronic GVHD and NRM as well as lower LFS and OS. Among pediatric patients receiving HSCT for AML in CR1, the use of BuCyMel conditioning proved superior to TBICy and BuCy in reducing relapse and improving LFS.

Original languageEnglish
Pages (from-to)467-474
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume23
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Acute Myeloid Leukemia
Transplantation
Pediatrics
Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Survival
Cyclophosphamide
Busulfan
Leukemia
Mortality
Stem Cells
Conditioning (Psychology)
Recurrence
Unrelated Donors
Melphalan
Whole-Body Irradiation
Registries
Siblings
Retrospective Studies
Bone Marrow

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. / Lucchini, Giovanna; Labopin, Myriam; Beohou, Eric; Dalissier, Arnauld; Dalle, Jean Hughes; Cornish, Jacqueline; Zecca, Marco; Samarasinghe, Sujith; Gibson, Brenda; Locatelli, Franco; Bertrand, Yves; Abdel-Rahman, Fawzi; Socie, Gerald; Sundin, Mikael; Lankester, Arjan; Sedlacek, Peter; Hamladji, Rose Marie; Heilmann, Carsten; Afanasyev, Boris; Hough, Rachel; Peters, Cristina; Bader, Peter; Veys, Paul.

In: Biology of Blood and Marrow Transplantation, Vol. 23, No. 3, 01.03.2017, p. 467-474.

Research output: Contribution to journalArticle

Lucchini, G, Labopin, M, Beohou, E, Dalissier, A, Dalle, JH, Cornish, J, Zecca, M, Samarasinghe, S, Gibson, B, Locatelli, F, Bertrand, Y, Abdel-Rahman, F, Socie, G, Sundin, M, Lankester, A, Sedlacek, P, Hamladji, RM, Heilmann, C, Afanasyev, B, Hough, R, Peters, C, Bader, P & Veys, P 2017, 'Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation', Biology of Blood and Marrow Transplantation, vol. 23, no. 3, pp. 467-474. https://doi.org/10.1016/j.bbmt.2016.11.022
Lucchini, Giovanna ; Labopin, Myriam ; Beohou, Eric ; Dalissier, Arnauld ; Dalle, Jean Hughes ; Cornish, Jacqueline ; Zecca, Marco ; Samarasinghe, Sujith ; Gibson, Brenda ; Locatelli, Franco ; Bertrand, Yves ; Abdel-Rahman, Fawzi ; Socie, Gerald ; Sundin, Mikael ; Lankester, Arjan ; Sedlacek, Peter ; Hamladji, Rose Marie ; Heilmann, Carsten ; Afanasyev, Boris ; Hough, Rachel ; Peters, Cristina ; Bader, Peter ; Veys, Paul. / Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. In: Biology of Blood and Marrow Transplantation. 2017 ; Vol. 23, No. 3. pp. 467-474.
@article{d3d036ba9ed642ffa15359ae8f59e04c,
title = "Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation",
abstract = "Hematopoietic stem cell transplantation (HSCT) represents the cornerstone of treatment in pediatric high-risk and relapsed acute myeloid leukemia (AML). The aim of the present study was to compare outcomes of pediatric patients with AML undergoing HSCT using 3 different conditioning regimens: total body irradiation (TBI) and cyclophosphamide (Cy); busulfan (Bu) and Cy; or Bu, Cy, and melphalan (Mel). In this retrospective study, registry data for patients > 2 and <18 years age undergoing matched allogeneic HSCT for AML in first complete remission (CR1) in 204 European Group for Blood and Marrow Transplantation centers between 2000 and 2010 were analyzed. Data were available for 631 patients; 458 patients received stem cells from a matched sibling donor and 173 from a matched unrelated donor. For 440 patients, bone marrow was used as stem cell source, and 191 patients received peripheral blood stem cells. One hundred nine patients received TBICy, 389 received BuCy, and 133 received BuCyMel as their preparatory regimen. Median follow-up was 55 months. Patients receiving BuCyMel showed a lower incidence of relapse at 5 years (14.7{\%} versus 31.5{\%} in BuCy versus 30{\%} in TBICy, P < .01) and higher overall survival (OS) (76.6{\%} versus 64{\%} versus 64.5{\%}, P = .04) and leukemia-free survival (LFS) (74.5{\%} versus 58{\%} versus 61.9{\%}, P < .01), with a comparable nonrelapse mortality (NRM) (10.8{\%} versus 10.5{\%} versus 8.1{\%}, P = .79). Acute graft-versus-host disease (GVHD) grades III and IV but not chronic GVHD, was higher in patients receiving BuCyMel. Older age at HSCT had an adverse impact on NRM and the use of peripheral blood as stem cell source was associated with increased chronic GVHD and NRM as well as lower LFS and OS. Among pediatric patients receiving HSCT for AML in CR1, the use of BuCyMel conditioning proved superior to TBICy and BuCy in reducing relapse and improving LFS.",
author = "Giovanna Lucchini and Myriam Labopin and Eric Beohou and Arnauld Dalissier and Dalle, {Jean Hughes} and Jacqueline Cornish and Marco Zecca and Sujith Samarasinghe and Brenda Gibson and Franco Locatelli and Yves Bertrand and Fawzi Abdel-Rahman and Gerald Socie and Mikael Sundin and Arjan Lankester and Peter Sedlacek and Hamladji, {Rose Marie} and Carsten Heilmann and Boris Afanasyev and Rachel Hough and Cristina Peters and Peter Bader and Paul Veys",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.bbmt.2016.11.022",
language = "English",
volume = "23",
pages = "467--474",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation

AU - Lucchini, Giovanna

AU - Labopin, Myriam

AU - Beohou, Eric

AU - Dalissier, Arnauld

AU - Dalle, Jean Hughes

AU - Cornish, Jacqueline

AU - Zecca, Marco

AU - Samarasinghe, Sujith

AU - Gibson, Brenda

AU - Locatelli, Franco

AU - Bertrand, Yves

AU - Abdel-Rahman, Fawzi

AU - Socie, Gerald

AU - Sundin, Mikael

AU - Lankester, Arjan

AU - Sedlacek, Peter

AU - Hamladji, Rose Marie

AU - Heilmann, Carsten

AU - Afanasyev, Boris

AU - Hough, Rachel

AU - Peters, Cristina

AU - Bader, Peter

AU - Veys, Paul

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Hematopoietic stem cell transplantation (HSCT) represents the cornerstone of treatment in pediatric high-risk and relapsed acute myeloid leukemia (AML). The aim of the present study was to compare outcomes of pediatric patients with AML undergoing HSCT using 3 different conditioning regimens: total body irradiation (TBI) and cyclophosphamide (Cy); busulfan (Bu) and Cy; or Bu, Cy, and melphalan (Mel). In this retrospective study, registry data for patients > 2 and <18 years age undergoing matched allogeneic HSCT for AML in first complete remission (CR1) in 204 European Group for Blood and Marrow Transplantation centers between 2000 and 2010 were analyzed. Data were available for 631 patients; 458 patients received stem cells from a matched sibling donor and 173 from a matched unrelated donor. For 440 patients, bone marrow was used as stem cell source, and 191 patients received peripheral blood stem cells. One hundred nine patients received TBICy, 389 received BuCy, and 133 received BuCyMel as their preparatory regimen. Median follow-up was 55 months. Patients receiving BuCyMel showed a lower incidence of relapse at 5 years (14.7% versus 31.5% in BuCy versus 30% in TBICy, P < .01) and higher overall survival (OS) (76.6% versus 64% versus 64.5%, P = .04) and leukemia-free survival (LFS) (74.5% versus 58% versus 61.9%, P < .01), with a comparable nonrelapse mortality (NRM) (10.8% versus 10.5% versus 8.1%, P = .79). Acute graft-versus-host disease (GVHD) grades III and IV but not chronic GVHD, was higher in patients receiving BuCyMel. Older age at HSCT had an adverse impact on NRM and the use of peripheral blood as stem cell source was associated with increased chronic GVHD and NRM as well as lower LFS and OS. Among pediatric patients receiving HSCT for AML in CR1, the use of BuCyMel conditioning proved superior to TBICy and BuCy in reducing relapse and improving LFS.

AB - Hematopoietic stem cell transplantation (HSCT) represents the cornerstone of treatment in pediatric high-risk and relapsed acute myeloid leukemia (AML). The aim of the present study was to compare outcomes of pediatric patients with AML undergoing HSCT using 3 different conditioning regimens: total body irradiation (TBI) and cyclophosphamide (Cy); busulfan (Bu) and Cy; or Bu, Cy, and melphalan (Mel). In this retrospective study, registry data for patients > 2 and <18 years age undergoing matched allogeneic HSCT for AML in first complete remission (CR1) in 204 European Group for Blood and Marrow Transplantation centers between 2000 and 2010 were analyzed. Data were available for 631 patients; 458 patients received stem cells from a matched sibling donor and 173 from a matched unrelated donor. For 440 patients, bone marrow was used as stem cell source, and 191 patients received peripheral blood stem cells. One hundred nine patients received TBICy, 389 received BuCy, and 133 received BuCyMel as their preparatory regimen. Median follow-up was 55 months. Patients receiving BuCyMel showed a lower incidence of relapse at 5 years (14.7% versus 31.5% in BuCy versus 30% in TBICy, P < .01) and higher overall survival (OS) (76.6% versus 64% versus 64.5%, P = .04) and leukemia-free survival (LFS) (74.5% versus 58% versus 61.9%, P < .01), with a comparable nonrelapse mortality (NRM) (10.8% versus 10.5% versus 8.1%, P = .79). Acute graft-versus-host disease (GVHD) grades III and IV but not chronic GVHD, was higher in patients receiving BuCyMel. Older age at HSCT had an adverse impact on NRM and the use of peripheral blood as stem cell source was associated with increased chronic GVHD and NRM as well as lower LFS and OS. Among pediatric patients receiving HSCT for AML in CR1, the use of BuCyMel conditioning proved superior to TBICy and BuCy in reducing relapse and improving LFS.

UR - http://www.scopus.com/inward/record.url?scp=85009423408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009423408&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2016.11.022

DO - 10.1016/j.bbmt.2016.11.022

M3 - Article

AN - SCOPUS:85009423408

VL - 23

SP - 467

EP - 474

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 3

ER -